Streptozotocin (STZ)-induced Type 1 Diabetes Model Development

Type 1 diabetes (T1D) is a chronic autoimmune condition characterized by the body's own immune system attacking and destroying insulin-producing beta cells in the pancreas. This leads to an absolute deficiency of insulin, a hormone essential for regulating blood glucose levels.

The prevalence of T1D has been increasing globally, emphasizing the need for effective therapeutic interventions. To develop these therapeutics, a reliable and representative model of T1D is crucial. This is where the streptozotocin (STZ)-induced type 1 diabetes model development services offered by Protheragen come into play.